<div style="position: relative; display: block; max-width: 100%;"><div style="padding-top: 56.25%;"><iframe src="//players.brightcove.net/4365621440001/216a41e4-093d-49b1-831c-dbf5b8ca99d9_default/index.html?videoId=6029022259001" <!-- [et_pb_line_break_holder] -->allowfullscreen <!-- [et_pb_line_break_holder] -->webkitallowfullscreen <!-- [et_pb_line_break_holder] -->mozallowfullscreen <!-- [et_pb_line_break_holder] -->allow="encrypted-media" <!-- [et_pb_line_break_holder] -->style="position: absolute; top: 0px; right: 0px; bottom: 0px; left: 0px; width: 100%; height: 100%;"></iframe></div></div><!-- [et_pb_line_break_holder] -->

Department of Medicine Grand Rounds
June 12, 2018

Bench to Bedside: Mechanism-based treatments for hemoglobinopathies

Gregory J. Kato, MD
Professor of Medicine, Division of Hematology/Oncology
Director, Adult Sickle Cell Center of Excellence
Heart, Lung, Blood and Vascular Medicine Institute University of Pittsburgh School of Medicine

Mitchell J. Weiss, MD, PhD
Chairman, Department of Hematology
Arthur Nienhuis Endowed Chair in Hematology St. Jude Children’s Research Hospital

View Presentation via BrightCove  |  CME Module